Omar Alhalabi

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 23

Top Venues

Journal of cutaneous pathology

Current oncology (Toronto, Ont.)

The oncologist

Biomedicines

University of Texas MD Anderson Cancer Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Texas MD Anderson Cancer Center Jul 01 2017 - Jun 30 2020

United States

Hematology/Medical Oncology :: Cancer Medicine

Publications

Woo Cheal Cho, Rayan Saade, Priyardhisini Nagarajan, Leomar Y Ballester, Denái R Milton, Mario L Marques-Piubelli, Courtney Hudgens, Debora Ledesma, Kelly Nelson, Doina Ivan, Miao Zhang, Carlos A Torres-Cabala, Matthew Campbell, Omar Alhalabi, Victor G Prieto, Ignacio I Wistuba, Bita Esmaeli, Jonathan L Curry
Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. Journal of cutaneous pathology 51 (5) (2024)
Woo Cheal Cho, Rayan Saade, Priyardhisini Nagarajan, Leomar Y Ballester, Denái R Milton, Mario L Marques-Piubelli, Courtney Hudgens, Debora Ledesma, Kelly Nelson, Doina Ivan, Miao Zhang, Carlos A Torres-Cabala, Matthew Campbell, Omar Alhalabi, Victor G Prieto, Ignacio I Wistuba, Bita Esmaeli, Jonathan L Curry
Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. Journal of cutaneous pathology 51 (5) (2024)
Woo Cheal Cho, Rayan Saade, Priyardhisini Nagarajan, Leomar Y Ballester, Denái R Milton, Mario L Marques-Piubelli, Courtney Hudgens, Debora Ledesma, Kelly Nelson, Doina Ivan, Miao Zhang, Carlos A Torres-Cabala, Matthew Campbell, Omar Alhalabi, Victor G Prieto, Ignacio I Wistuba, Bita Esmaeli, Jonathan L Curry
Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. Journal of cutaneous pathology (2024)
Mohammad Jad Moussa, Matthew T Campbell, Omar Alhalabi
Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand? Biomedicines 12 (3) (2024)
Mohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, Sagar A Naik, Vivek Subbiah, Matthew T Campbell, Pavlos Msaouel, Parminder Singh, Omar Alhalabi
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Current oncology (Toronto, Ont.) 31 (6) (2024)
Mohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, Sagar A Naik, Vivek Subbiah, Matthew T Campbell, Pavlos Msaouel, Parminder Singh, Omar Alhalabi
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Current oncology (Toronto, Ont.) 31 (6) (2024)
Woo Cheal Cho, Rayan Saade, Priyardhisini Nagarajan, Leomar Y Ballester, Denái R Milton, Mario L Marques-Piubelli, Courtney Hudgens, Debora Ledesma, Kelly Nelson, Doina Ivan, Miao Zhang, Carlos A Torres-Cabala, Matthew Campbell, Omar Alhalabi, Victor G Prieto, Ignacio I Wistuba, Bita Esmaeli, Jonathan L Curry
Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. Journal of cutaneous pathology 51 (5) (2024)
Mohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, Sagar A Naik, Vivek Subbiah, Matthew T Campbell, Pavlos Msaouel, Parminder Singh, Omar Alhalabi
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Current oncology (Toronto, Ont.) 31 (6) (2024)
Mohammad Jad Moussa, Matthew T Campbell, Omar Alhalabi
Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand? Biomedicines 12 (3) (2024)
Javier Leo, Eleonora Dondossola, Kaitlin J Basham, Nathaniel R Wilson, Omar Alhalabi, Jianjun Gao, Katherine C Kurnit, Michael G White, Jennifer Leigh McQuade, Shannon Neville Westin, Elizabeth A Wellberg, Daniel E Frigo
Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer. Endocrinology (2023)
Xiaofan Lu, Nassim Tawanaie Pour Sedehi, Xiaoping Su, Fangrong Yan, Omar Alhalabi, Nizar M Tannir, Gabriel G Malouf
Racial Disparities in MiT Family Translocation Renal Cell Carcinoma. The oncologist (2023)
Omar Alhalabi, Roman Groisberg, Ralph Zinner, Andrew W Hahn, Aung Naing, Shizhen Zhang, Apostolia-Maria Tsimberidou, Jordi Rodon, Siqing Fu, Timothy Anthony Yap, David S Hong, Ming Sun, Yunfang Jiang, Shubham Pant, Amishi Y Shah, Amado J Zurita, Nizar M Tannir, Raghunandan Vikram, Jason Roszik, Funda Meric-Bernstam, Vivek Subbiah
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ precision oncology 7 (1) (2023)
Omar Alhalabi, Jonathan Thouvenin, Sylvie Négrier, Yann-Alexandre Vano, Luca Campedel, Elshad Hasanov, Ziad Bakouny, Andrew W Hahn, Mehmet Asim Bilen, Pavlos Msaouel, Toni K Choueiri, Srinivas R Viswanathan, Kanishka Sircar, Laurence Albiges, Gabriel G Malouf, Nizar M Tannir
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. The oncologist (2023)
Arlene O Siefker-Radtke, Diana Cauley, Omar Alhalabi
Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Andrew W Hahn, Devaki Shilpa Surasi, Paul V Viscuse, Tharakeswara K Bathala, Andrew J Wiele, Matthew T Campbell, Amado J Zurita, Amishi Y Shah, Eric Jonasch, Jianjun Gao, Sangeeta Goswami, Omar Alhalabi, Priya Rao, Kanishka Sircar, Nizar M Tannir, Pavlos Msaouel
Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. The oncologist (2023)
Omar Alhalabi, Jianfeng Chen, Yuxue Zhang, Yang Lu, Qi Wang, Sumankalai Ramachandran, Rebecca S Slack Tidwell, Guangchun Han, Xinmiao Yan, Jieru Meng, Ruiping Wang, Anh G Hoang, Wei-Lien Wang, Jian Song, Lidia Lopez, Alex Andreev-Drakhlin, Arlene O Siefker-Radtke, Xinqiao Zhang, William F Benedict, Amishi Yogesh Shah, Jennifer Wang, Pavlos Msaouel, Miao Zhang, Charles C Guo, Bogdan Czerniak, Carmen Behrens, Luisa Maren Solis Soto, Vassiliki Papadimitrakopoulou, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jiun-Kae Jack Lee, Jack A Roth, Stephen G Swisher, Ignacio Wistuba, John Victor Heymach, Jing Wang, Matthew T Campbell, Eleni Efstathiou, Mark Titus, Christopher L Logothetis, Thai H Ho, Jianjun Zhang, Linghua Wang, Jianjun Gao
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature communications 13 (1) (2022)
Omar Alhalabi, Zaid Soomro, Ryan Sun, Elshad Hasanov, Aya Albittar, Debasish Tripathy, Vicente Valero, Nuhad K Ibrahim
Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. NPJ breast cancer 7 (1) (2021)
Omar Alhalabi, Matthew T Campbell, Lianchun Xiao, Ana C Adriazola, Nathaniel R Wilson, Arlene O Siefker-Radtke, Paul G Corn, Amado Zurita, Eric Jonasch, Jianjun Gao, Mehrad Adibi, Ashish M Kamat, Neema Navai, Louis L Pisters, Colin Dinney, Surena F Matin, Amishi Y Shah
Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI compass 3 (1) (2021)
Omar Alhalabi, Elshad Hasanov, Nathaniel R Wilson, John Araujo, Jianbo Wang, Matthew T Campbell, Sangeeta Goswami, Amishi Y Shah, Jianjun Gao, Pavlos Msaouel, Nizar M Tannir
Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. International journal of cancer 149 (2) (2021)
Jonathan Thouvenin, Nieves Martínez Chanzá, Omar Alhalabi, Hervé Lang, Nizar M Tannir, Philippe Barthélémy, Gabriel G Malouf
Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions. Cancers 13 (17) (2021)
Guangchun Han, Guoliang Yang, Dapeng Hao, Yang Lu, Kyaw Zin Thein, Benjamin Scott S Simpson, Jianfeng Chen, Ryan Sun, Omar Alhalabi, Ruiping Wang, Minghao Dang, Enyu Dai, Shaojun Zhang, Fengqi Nie, Shuangtao Zhao, Charles Guo, Ameer Hamza, Bogdan Czerniak, Chao Cheng, Arlene Siefker-Radtke, Krishna P Bhat, P Andrew Futreal, Guang Peng, Jennifer A Wargo, Weiyi Peng, Humam Kadara, Jaffer A Ajani, Charles Swanton, Kevin Litchfield, Jordi Rodon Ahnert, Jianjun Gao, Linghua Wang
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nature communications 12 (1) (2021)
Omar Alhalabi, Andrew W Hahn, Pavlos Msaouel, Alexander Y Andreev-Drakhlin, Funda Meric-Bernstam, Aung Naing, Sarina Piha-Paul, Filip Janku, Shubham Pant, Timothy Anthony Yap, David S Hong, Siqing Fu, Daniel Karp, Matthew T Campbell, Hung Le, Amishi Y Shah, Nizar M Tannir, Arlene O Siefker-Radtke, Jianjun Gao, Jason Roszik, Vivek Subbiah
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Molecular cancer research : MCR 19 (3) (2020)
Jianjun Gao, Neema Navai, Omar Alhalabi, Arlene Siefker-Radtke, Matthew T Campbell, Rebecca S Slack Tidwell, Charles C Guo, Ashish M Kamat, Surena F Matin, John C Araujo, Amishi Y Shah, Pavlos Msaouel, Paul Corn, Jianbo Wang, John N Papadopoulos, Shalini S Yadav, Jorge M Blando, Fei Duan, Sreyashi Basu, Wenbin Liu, Yu Shen, Yuwei Zhang, Marc Daniel Macaluso, Ying Wang, Jianfeng Chen, Jianhua Zhang, P Andrew Futreal, Colin Dinney, James P Allison, Sangeeta Goswami, Padmanee Sharma
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nature medicine 26 (12) (2020)

Omar Alhalabi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Omar Alhalabi